SCHEMBL2760466

SCHEMBL2760466

CC[C@H]1CN2CCC1C[C@@H]2[C@H](N)c1ccnc2ccc(OC)cc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 12/20 0.80
ALDH1A1 P00352 5/20 0.80
HSD17B10 Q99714 5/20 0.80
KDM4E B2RXH2 5/20 0.80
ADRA2A P08913 4/20 0.80
SLC6A4 P31645 4/20 0.80
OPRM1 P35372 4/20 0.80
KCNH2 Q12809 4/20 0.80
HPGD P15428 3/20 0.80
CYP3A4 P08684 3/20 0.80
TSHR P16473 2/20 0.80
MEN1 O00255 2/20 0.80
KMT2A Q03164 2/20 0.80
SLC6A3 Q01959 2/20 0.80
CHRM2 P08172 1/20 0.80
SCN1A P35498 4/20 0.65
SCN2A Q99250 4/20 0.65
SCN3A Q9NY46 4/20 0.65
CALCRL Q16602 2/20 0.59
SLC22A1 O15245 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15435445 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL15435414 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL16558836 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL12268184 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL25209392 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL15435448 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL25265154 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL25209394 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL25188332 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A
SCHEMBL518372 1.00 CYP2D6 (0.80) CYP2D6ALDH1A1HSD17B10KDM4EADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004424-A1 MICHAEL REACTION WITH RECOVERY OF THE CATALYST CYP2E1, CYP11B2, CYP11B1 CYP2D6 40/4885ALDH1A1 118/4885HSD17B10 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.